Developer docs
API playgroundTry for free, no card

Search company profiles

TetMedical

Full company profile

uuid0004ws6

Namestring
TetMedical
Legal namestring
TETmedical, Inc.
Websiteurl
tetmedical.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

TETmedical, Inc. (also doing business as Tethered Enzyme Technologies) is a Delaware C-corp clinical-stage nanomedicine company founded in December 2021, with operations in Ithaca, NY and Fair Haven, NJ. It develops in vitro diagnostics (IVDs) built on its proprietary Tethered Enzyme Technology (TET) platform, licensed from Cornell University. The TET platform consists of "nanobots" — silica nanoparticles to which thousands of enzymes are tethered with active sites facing outward — that perform coupled catalytic reactions for biomarker detection. The architecture provides intrinsic signal amplification (each enzyme performing up to ~1,000 conversions/second), enabling detection rates the company describes as thousands of times faster than antibody assays.

The company's lead and only clinical-stage product is NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test), an IVD intended to aid diagnosis of acute ischemic stroke by measuring NSE functional enzymatic activity (rather than protein concentration) in blood plasma. By measuring activity, the test distinguishes recently released active NSE (half-life <6 hours) from inactive protein, returning results within 30 seconds to 5 minutes using standard hospital plate readers. The clinical thesis addresses the ~17% of acute ischemic strokes missed by standard CT imaging and the need to differentiate true strokes from stroke mimics before administering tPA. NSE-FAST has been studied in a pilot at Guthrie Stroke Center and a feasibility study at Weill Cornell Medicine, with a multi-center pivotal study planned for Q4 2026 and FDA marketing submission targeted for Q4 2027. A pipeline of additional TET-based assays exists in respiratory virus differential diagnostics, microRNA-based cancer tests (canine hemangiosarcoma, endometriosis, breast cancer), and at-home liver function (ALT/AST) tests.

TETmedical is pre-revenue. Its intended business model is direct sales of NSE-FAST diagnostic tests to hospital emergency departments and clinical laboratories, designed to integrate into existing stroke workflows and standard plate readers to ease adoption. Preliminary US stroke market potential is estimated at $400M–$800M annually. To date the company has been financed largely through non-dilutive sources: ~$4M in equity, ~$2M in NY State and NIH grant awards, and an underlying technology base supported by $6M+ in academic grants (including an NIH Pioneer Award); as of 2024 it was funded by three grants totaling $1.25M with applications pending for another $1.4M. The team is small (1–10 employees), led by CEO and co-founder David Fischell (a serial med-tech entrepreneur and Cornell Trustee Emeritus) alongside Cornell co-founders Alex Travis (Director) and Roy Cohen (CSO).

Short descriptiontext

TETmedical is a clinical-stage nanomedicine company developing in vitro diagnostics on its Cornell-licensed Tethered Enzyme Technology platform. Its lead product, NSE-FAST, is a rapid blood test aiding acute ischemic stroke diagnosis for hospital emergency departments and clinical laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersIthaca, United States
HQ citystring
Ithaca
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
in vitro diagnostics, stroke diagnostic assays, nanomedicine platform, biosensor technology, rapid diagnostic tests
Industry3 codes
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
In Vitro Diagnostics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1NSE-FAST Diagnostic Test Sales
TypeOne Time License
Description

Revenue from sale of the NSE-FAST in-vitro diagnostic test for stroke diagnosis to hospital emergency departments and clinical laboratories. Test is designed to be used with standard plate readers already present in hospitals.

tetmedical.com
2Pipeline Diagnostic Products
TypeOne Time License
Description

Future revenue streams from additional diagnostic products including respiratory virus differential diagnostics, microRNA-based cancer diagnostics (canine hemangiosarcoma, endometriosis, breast cancer), and at-home liver function tests (ALT/AST).

tetmedical.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

TETmedical develops and sells rapid in-vitro diagnostic assays built on its proprietary Tethered Enzyme Technology (TET) platform, beginning with the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test) intended to aid in the diagnosis of acute ischemic stroke by measuring NSE functional activity in blood plasma within minutes using standard hospital plate readers. The product targets emergency department clinicians and is currently in clinical studies with FDA Breakthrough Device Designation, while additional pipeline diagnostics for respiratory viruses, microRNA biomarkers, and at-home liver function (ALT/AST) tests are in development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 17% of acute ischemic strokes currently missed by standard CT imaging
+4 more records
Product overview1 text field

TetMedical is a clinical-stage platform nanomedicine company developing in vitro diagnostics based on its proprietary Tethered Enzyme Technology (TET). The company's first product is the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test), an IVD for stroke detection. The TET platform consists of nanobots with thousands of enzymes tethered to silica nanoparticles, enabling rapid, high-sensitivity detection. The pipeline includes tests for viral detection, microRNA biomarkers, and liver function tests.

Product and service4 records
1NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test)
CategoryIn Vitro Diagnostics — Stroke
Description

Rapid in-vitro diagnostic assay designed to aid in the diagnosis of acute ischemic stroke by measuring Neuron Specific Enolase functional activity in blood plasma using TET nanobots, intended for use with standard hospital plate readers in the Emergency Department alongside STAT blood work and CT imaging.

2Respiratory Virus Diagnostic Tests
CategoryIn Vitro Diagnostics — Infectious Disease
Description

TET-based rapid differential diagnostic test for respiratory viral infections including influenza, COVID-19, and common cold, using RNA and DNA detection without thermocycling.

3microRNA Diagnostic Tests (Canine Hemangiosarcoma; Endometriosis; Breast Cancer)
CategoryIn Vitro Diagnostics — Oncology / microRNA Biomarkers
Description

Planned TET-based point-of-care tests for specific microRNA biomarkers, with initial development in canine hemangiosarcoma and future applications in endometriosis and breast cancer.

4At-Home Liver Function Tests (ALT/AST)
CategoryIn Vitro Diagnostics — Liver Function / At-Home
Description

At-home test capable of measuring ALT and AST liver enzymes without venipuncture, using lateral flow blood separation integrated with TET biosensors.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

TETmedical received gap funding and commercialization support from Cornell's Ignite Cornell Research: Lab to Market program managed by Cornell Center for Technology Licensing. Program has helped 32 Ignite-supported startups secure $231 million in follow-on funding and execute 38 licenses and options since founding four years ago.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-01
Description

TETmedical moved into Cornell Center for Life Science Ventures incubator in November 2024 before relocating to new facility at 22 Thornwood Drive in Ithaca, NY. Cornell Center for Life Science Ventures manages the Ignite Cornell Research: Lab to Market program that provided gap funding and commercialization support to TETmedical.

3Biocom Consulting
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-03-01
Description

TETmedical hired Biocom Consulting to conduct market research including 7 in-depth telephone interviews with U.S. experts (4 Emergency Department Chairs and 3 Neurologists) between January 27th and March 9th, 2023 to understand current diagnostic stroke protocols, determine current management of stroke cases, and gauge physician interest in blinded product profile.

tetmedical.com
4Guthrie Stroke Center
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Pilot stroke study conducted at Guthrie Stroke Center in Pennsylvania demonstrating utility of NSE-FAST for detecting acute brain injury. Results pending publication.

tetmedical.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Follow-up feasibility study in progress at Weill Cornell Medicine to evaluate NSE-FAST in clinical settings.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Early-stage product development for canine hemangiosarcoma test using microRNA biomarkers identified by Dr. Scott Coonrod at Cornell's Baker Institute for Animal Health, supported by Cornell's Riney Canine Health Center.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-12-01
Description

TETmedical emerged out of groundbreaking innovations originating at Cornell University. Co-founded by Professors Alex Travis and Roy Cohen of Cornell. Technology based on more than $6M in grant funding to professors Travis and Cohen. IP licensed from Cornell University including 4 issued and 3 pending patents. Company history states TET was transitioning from Cornell labs of Drs. Cohen and Travis to Cornell Center for Life Science Ventures incubator.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1BioDirection
TypeDirect peer
Description

Privately held developer of rapid point-of-care blood-based diagnostics for traumatic brain injury and stroke. Most directly comparable to TETmedical by targeting rapid biomarker-based brain-injury detection in acute care settings.

2Banyan Biomarkers
TypeDirect peer
Description

Developer of blood-based biomarker assays (GFAP, UCH-L1) for traumatic brain injury and stroke triage. Directly comparable as a competing blood-based biomarker diagnostic approach for acute brain injury in ED settings.

3Abbott Diagnostics
TypeBroad incumbent
Description

Global IVD leader whose i-STAT and troponin franchise is the explicit benchmark TETmedical cites for NSE-FAST. Large installed base in hospital EDs and clinical chemistry labs makes Abbott the most relevant incumbent comparator.

TypeBroad incumbent
Description

World's largest IVD company with extensive neurology and cardiac biomarker pipelines. Comparable as a broad incumbent with the resources and channels to enter or expand in stroke biomarkers if the market validates.

TypeBroad incumbent
Description

Major IVD player (ADVIA Centaur, Atellica) with established cardiac and neurology biomarker menu. Comparable broad incumbent with deep hospital lab penetration that could compete in rapid stroke diagnostics.

TypeEmerging player
Description

Developer of the Simoa single-molecule array platform for ultra-sensitive protein biomarker detection. Comparable as an emerging, platform-based biomarker detection company pursuing neurological disease applications with novel sensitivity claims.

TypeEmerging player
Description

Specialty biomarker detection platform company serving pharma, clinical research, and translational applications. Comparable as a platform biomarker detection company with multiplexed assay capabilities used in clinical research.

TypeBroad incumbent
Description

Established clinical diagnostics and life science research company with a broad IVD menu. Comparable as a broad incumbent with hospital lab relationships that could expand into stroke biomarkers.

TypeEmerging player
Description

Licensor of tau-related biomarker technology for neurodegenerative disease diagnostics. Comparable as an emerging player focused on brain-injury/neurodegeneration biomarker detection in clinical research and diagnostics.

TypeEmerging player
Description

Developer of IntelliSep, a rapid cellular biomarker diagnostic for sepsis cleared by FDA. Comparable as an emerging, platform-based rapid IVD company targeting acute-care hospital decision-making with novel biomarker detection.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TetMedical

In Vitro Diagnosticstetmedical.com

TETmedical is a clinical-stage nanomedicine company developing in vitro diagnostics on its Cornell-licensed Tethered Enzyme Technology platform. Its lead product, NSE-FAST, is a rapid blood test aiding acute ischemic stroke diagnosis for hospital emergency departments and clinical laboratories.

What TetMedical does

TETmedical, Inc. (also doing business as Tethered Enzyme Technologies) is a Delaware C-corp clinical-stage nanomedicine company founded in December 2021, with operations in Ithaca, NY and Fair Haven, NJ. It develops in vitro diagnostics (IVDs) built on its proprietary Tethered Enzyme Technology (TET) platform, licensed from Cornell University. The TET platform consists of "nanobots" — silica nanoparticles to which thousands of enzymes are tethered with active sites facing outward — that perform coupled catalytic reactions for biomarker detection. The architecture provides intrinsic signal amplification (each enzyme performing up to ~1,000 conversions/second), enabling detection rates the company describes as thousands of times faster than antibody assays.

The company's lead and only clinical-stage product is NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test), an IVD intended to aid diagnosis of acute ischemic stroke by measuring NSE functional enzymatic activity (rather than protein concentration) in blood plasma. By measuring activity, the test distinguishes recently released active NSE (half-life <6 hours) from inactive protein, returning results within 30 seconds to 5 minutes using standard hospital plate readers. The clinical thesis addresses the ~17% of acute ischemic strokes missed by standard CT imaging and the need to differentiate true strokes from stroke mimics before administering tPA. NSE-FAST has been studied in a pilot at Guthrie Stroke Center and a feasibility study at Weill Cornell Medicine, with a multi-center pivotal study planned for Q4 2026 and FDA marketing submission targeted for Q4 2027. A pipeline of additional TET-based assays exists in respiratory virus differential diagnostics, microRNA-based cancer tests (canine hemangiosarcoma, endometriosis, breast cancer), and at-home liver function (ALT/AST) tests.

TETmedical is pre-revenue. Its intended business model is direct sales of NSE-FAST diagnostic tests to hospital emergency departments and clinical laboratories, designed to integrate into existing stroke workflows and standard plate readers to ease adoption. Preliminary US stroke market potential is estimated at $400M–$800M annually. To date the company has been financed largely through non-dilutive sources: ~$4M in equity, ~$2M in NY State and NIH grant awards, and an underlying technology base supported by $6M+ in academic grants (including an NIH Pioneer Award); as of 2024 it was funded by three grants totaling $1.25M with applications pending for another $1.4M. The team is small (1–10 employees), led by CEO and co-founder David Fischell (a serial med-tech entrepreneur and Cornell Trustee Emeritus) alongside Cornell co-founders Alex Travis (Director) and Roy Cohen (CSO).

TetMedical firmographics

Firmographics
Name
TetMedical
Legal name
TETmedical, Inc.
Website
https://tetmedical.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
TETmedical is a clinical-stage nanomedicine company developing in vitro diagnostics on its Cornell-licensed Tethered Enzyme Technology platform. Its lead product, NSE-FAST, is a rapid blood test aiding acute ischemic stroke diagnosis for hospital emergency departments and clinical laboratories.
Ownership category
akta.pro rank

TetMedical industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • In vitro diagnostics
  • Stroke diagnostic assays
  • Nanomedicine platform
  • Biosensor technology
  • Rapid diagnostic tests

Where TetMedical is headquartered

Location

Headquarters

HQ city
Ithaca
HQ country
United States
HQ region
North America

Offices2 records

Markets served

TetMedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. NSE-FAST Diagnostic Test Sales: Revenue from sale of the NSE-FAST in-vitro diagnostic test for stroke diagnosis to hospital emergency departments and clinical laboratories. Test is designed to be used with standard plate readers already present in hospitals.
  2. Pipeline Diagnostic Products: Future revenue streams from additional diagnostic products including respiratory virus differential diagnostics, microRNA-based cancer diagnostics (canine hemangiosarcoma, endometriosis, breast cancer), and at-home liver function tests (ALT/AST).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

TetMedical product offering

Product offering

Core offering

TETmedical develops and sells rapid in-vitro diagnostic assays built on its proprietary Tethered Enzyme Technology (TET) platform, beginning with the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test) intended to aid in the diagnosis of acute ischemic stroke by measuring NSE functional activity in blood plasma within minutes using standard hospital plate readers. The product targets emergency department clinicians and is currently in clinical studies with FDA Breakthrough Device Designation, while additional pipeline diagnostics for respiratory viruses, microRNA biomarkers, and at-home liver function (ALT/AST) tests are in development.

Product overview

TetMedical is a clinical-stage platform nanomedicine company developing in vitro diagnostics based on its proprietary Tethered Enzyme Technology (TET). The company's first product is the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test), an IVD for stroke detection. The TET platform consists of nanobots with thousands of enzymes tethered to silica nanoparticles, enabling rapid, high-sensitivity detection. The pipeline includes tests for viral detection, microRNA biomarkers, and liver function tests.

Differentiator

Problem solved

Functional benefit

Products and services

  • NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test) Rapid in-vitro diagnostic assay designed to aid in the diagnosis of acute ischemic stroke by measuring Neuron Specific Enolase functional activity in blood plasma using TET nanobots, intended for use with standard hospital plate readers in the Emergency Department alongside STAT blood work and CT imaging.
  • Respiratory Virus Diagnostic Tests TET-based rapid differential diagnostic test for respiratory viral infections including influenza, COVID-19, and common cold, using RNA and DNA detection without thermocycling.
  • microRNA Diagnostic Tests (Canine Hemangiosarcoma; Endometriosis; Breast Cancer) Planned TET-based point-of-care tests for specific microRNA biomarkers, with initial development in canine hemangiosarcoma and future applications in endometriosis and breast cancer.
  • At-Home Liver Function Tests (ALT/AST) At-home test capable of measuring ALT and AST liver enzymes without venipuncture, using lateral flow blood separation integrated with TET biosensors.

Quantifiable outcome

  • 17% of acute ischemic strokes currently missed by standard CT imaging
  • +4 more outcomes

Companies that use TetMedical

Customer profile

Segments3 records

Ideal customer profiles1 record

TetMedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

TetMedical partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Cornell Ignite Cornell Research: Lab to Market ProgramcoreStrategic or Co-development Partner · 1 April 2025TETmedical received gap funding and commercialization support from Cornell's Ignite Cornell Research: Lab to Market program managed by Cornell Center for Technology Licensing. Program has helped 32 Ignite-supported startups secure $231 million in follow-on funding and execute 38 licenses and options since founding four years ago.
  • Cornell Center for Life Science VenturescoreStrategic or Co-development Partner · 1 November 2024TETmedical moved into Cornell Center for Life Science Ventures incubator in November 2024 before relocating to new facility at 22 Thornwood Drive in Ithaca, NY. Cornell Center for Life Science Ventures manages the Ignite Cornell Research: Lab to Market program that provided gap funding and commercialization support to TETmedical.
  • Biocom ConsultingminorImplementation/ SI/ Consulting Partner · 1 March 2023TETmedical hired Biocom Consulting to conduct market research including 7 in-depth telephone interviews with U.S. experts (4 Emergency Department Chairs and 3 Neurologists) between January 27th and March 9th, 2023 to understand current diagnostic stroke protocols, determine current management of stroke cases, and gauge physician interest in blinded product profile.
  • Guthrie Stroke CentercoreStrategic or Co-development Partner · 1 January 2023Pilot stroke study conducted at Guthrie Stroke Center in Pennsylvania demonstrating utility of NSE-FAST for detecting acute brain injury. Results pending publication.
  • Weill Cornell MedicinecoreStrategic or Co-development Partner · 1 January 2023Follow-up feasibility study in progress at Weill Cornell Medicine to evaluate NSE-FAST in clinical settings.
  • Cornell Riney Canine Health CenterminorStrategic or Co-development Partner · 1 January 2022Early-stage product development for canine hemangiosarcoma test using microRNA biomarkers identified by Dr. Scott Coonrod at Cornell's Baker Institute for Animal Health, supported by Cornell's Riney Canine Health Center.
  • Cornell UniversitycoreStrategic or Co-development Partner · 1 December 2021TETmedical emerged out of groundbreaking innovations originating at Cornell University. Co-founded by Professors Alex Travis and Roy Cohen of Cornell. Technology based on more than $6M in grant funding to professors Travis and Cohen. IP licensed from Cornell University including 4 issued and 3 pending patents. Company history states TET was transitioning from Cornell labs of Drs. Cohen and Travis to Cornell Center for Life Science Ventures incubator.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

TetMedical competitors and assessment

Company assessment

Direct peers

  • BioDirection: Privately held developer of rapid point-of-care blood-based diagnostics for traumatic brain injury and stroke. Most directly comparable to TETmedical by targeting rapid biomarker-based brain-injury detection in acute care settings.
  • Banyan Biomarkers: Developer of blood-based biomarker assays (GFAP, UCH-L1) for traumatic brain injury and stroke triage. Directly comparable as a competing blood-based biomarker diagnostic approach for acute brain injury in ED settings.

Broad incumbents

  • Abbott Diagnostics: Global IVD leader whose i-STAT and troponin franchise is the explicit benchmark TETmedical cites for NSE-FAST. Large installed base in hospital EDs and clinical chemistry labs makes Abbott the most relevant incumbent comparator.
  • Roche Diagnostics: World's largest IVD company with extensive neurology and cardiac biomarker pipelines. Comparable as a broad incumbent with the resources and channels to enter or expand in stroke biomarkers if the market validates.
  • Siemens Healthineers: Major IVD player (ADVIA Centaur, Atellica) with established cardiac and neurology biomarker menu. Comparable broad incumbent with deep hospital lab penetration that could compete in rapid stroke diagnostics.
  • Bio-Rad Laboratories: Established clinical diagnostics and life science research company with a broad IVD menu. Comparable as a broad incumbent with hospital lab relationships that could expand into stroke biomarkers.

Emerging players

  • Quanterix: Developer of the Simoa single-molecule array platform for ultra-sensitive protein biomarker detection. Comparable as an emerging, platform-based biomarker detection company pursuing neurological disease applications with novel sensitivity claims.
  • Meso Scale Diagnostics: Specialty biomarker detection platform company serving pharma, clinical research, and translational applications. Comparable as a platform biomarker detection company with multiplexed assay capabilities used in clinical research.
  • Cerveau Technologies: Licensor of tau-related biomarker technology for neurodegenerative disease diagnostics. Comparable as an emerging player focused on brain-injury/neurodegeneration biomarker detection in clinical research and diagnostics.
  • Cytovale: Developer of IntelliSep, a rapid cellular biomarker diagnostic for sepsis cleared by FDA. Comparable as an emerging, platform-based rapid IVD company targeting acute-care hospital decision-making with novel biomarker detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

TetMedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TetMedical leadership team

Management profile

Number of profiles

Profiles12 records

TetMedical funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TetMedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TetMedical

What does TetMedical do?

TETmedical develops and sells rapid in-vitro diagnostic assays built on its proprietary Tethered Enzyme Technology (TET) platform, beginning with the NSE-FAST (Neuron Specific Enolase Functional Activity Stroke Test) intended to aid in the diagnosis of acute ischemic stroke by measuring NSE functional activity in blood plasma within minutes using standard hospital plate readers. The product targets emergency department clinicians and is currently in clinical studies with FDA Breakthrough Device Designation, while additional pipeline diagnostics for respiratory viruses, microRNA biomarkers, and at-home liver function (ALT/AST) tests are in development.

Is TetMedical a public or private company?

TetMedical is a private company. It is classified as venture growth investor backed and is currently operating.

When was TetMedical founded?

TetMedical was founded in 2021. It employs 11 to 50 people.

Where is TetMedical based?

TetMedical is headquartered in Ithaca, United States, in the North America region.

How does TetMedical make money?

Two revenue lines are on record. NSE-FAST Diagnostic Test Sales are the primary driver. The others are pipeline Diagnostic Products.

Who are TetMedical's main competitors?

Direct peers on record are BioDirection and Banyan Biomarkers. Broad incumbents are Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers and Bio-Rad Laboratories. Emerging players are Quanterix, Meso Scale Diagnostics, Cerveau Technologies and Cytovale.

Does TetMedical have an API?

No public API is recorded for TetMedical.

What industry is TetMedical in?

TetMedical's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceTETmedical Names Arjun Ishwar Chief Commercial Officer to Lead Commercial Strategy and Accelerate NSE-FAST® Toward Market Launch and Rapid GrowthTETmedical appointed Arjun Ishwar as Chief Commercial Officer to lead commercial strategy for its NSE-FAST stroke test. The company plans a multi-center pivotal study in Q4 2026 and commercial launch in the U.S. and internationally. The test received FDA Breakthrough Device Designation in June 2026.Mirage NewsFDA Grants Breakthrough Status to Stroke Test TechTETmedical, a company co-founded by Cornell University researchers Dr. Alexander Travis and Dr. Roy Cohen, has received FDA Breakthrough Device Designation for NSE-FAST®, a rapid blood test designed to aid in the diagnosis of acute ischemic stroke. The test detects a biomarker associated with stroke and addresses a significant clinical gap—studies show nearly one in six strokes is initially missed, increasing risks of cognitive impairment, disability, and death. The Breakthrough Device Designation provides an accelerated regulatory pathway for continued development and FDA collaboration.Cornell ChronicleStroke test tech receives 'breakthrough' status from FDABaker Institute for Animal Health researchers Dr. Alexander Travis and Dr. Roy Cohen, together with Cornell Trustee Emeritus David Fischell, co-founded TETmedical to advance their stroke detection technology. The FDA has granted Breakthrough Device Designation to NSE-FAST®, the first rapid blood test designed to aid in diagnosing acute ischemic stroke, providing an accelerated pathway for clinical development. Studies show that nearly one in six strokes is initially missed, making rapid diagnosis critical to reduce cognitive impairment, disability, and death.GlobeNewswireTETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic StrokeThe FDA granted Breakthrough Device Designation to TETmedical's NSE-FAST®, a rapid in vitro diagnostic assay intended to aid in the diagnosis of acute ischemic stroke. The test addresses a significant diagnostic gap, as stroke is the leading missed diagnosis causing serious harm in emergency medicine, with approximately 17 percent of strokes currently missed by standard CT imaging. TETmedical plans to initiate a multi-center pivotal study in Q4 2026 and submit its marketing application to the FDA by Q4 2027.GlobeNewswireTETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic StrokeTETmedical announced that the FDA granted Breakthrough Device Designation to its NSE-FAST® rapid in vitro diagnostic assay intended to aid in the diagnosis of acute ischemic stroke, providing the company with prioritized access to FDA experts and enhanced regulatory interactions. The designation positions NSE-FAST® for potential inclusion in the FDA-CMS RAPID coverage pathway, which could accelerate Medicare reimbursement decisions following market authorization. TETmedical plans to initiate a multi-center pivotal study in Q4 2026, complete enrollment in the second half of 2027, and submit its marketing application to the FDA by Q4 2027.FinancialContent Business PageTETmedical Receives FDA Breakthrough Device Designation for NSE-FAST®, the First Rapid Test Designed to Aid in the Diagnosis of Acute Ischemic StrokeTETmedical, Inc. announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to its NSE-FAST® rapid blood test, designed to aid in the diagnosis of acute ischemic stroke. The test utilizes the company's patented Tethered Enzyme Technology to measure Neuron Specific Enolase functional activity in blood plasma. TETmedical plans to initiate a multi-center pivotal study in Q4 2026 and submit its marketing application to the FDA by Q4 2027.Cornell ChronicleResearch becomes reality for biomed startupsCornell's Ignite Cornell Research: Lab to Market program, managed by the Center for Technology Licensing, has provided gap funding and commercialization support to three early-stage biomedical startups: TETmedical (developing a rapid stroke blood test using tethered enzyme technology), Romix Biosciences (building a cell-free RNA extraction and disease profiling platform), and IVSonance (creating tools for IVF fertility treatment). Since its founding four years ago, the program has helped 32 Ignite-supported startups secure $231 million in follow-on funding and execute 38 licenses and options. The timing is significant as venture capital for deep tech startups has dwindled and government funding for technology translation remains uncertain, making university-based gap funding programs increasingly critical for advancing discoveries through the "valley of death" to market.Fingerlakes1.comCornell startups raise $34M as incubators drive innovationThree Cornell incubator graduates—Llume, Meiogenix, and TETmedical—raised $34 million and created 33 high-tech jobs. The companies, which developed a fiberoptic sensor, non-GMO plant breeding, and a stroke test, were honored at a Moving Up event on April 15.Cornell ChronicleDavid Fischell: Applied Physics is the Mother of InventionDavid Fischell, a serial entrepreneur and inventor, has developed numerous FDA-approved medical devices including the first drug-eluting stent for Johnson & Johnson, the NeuroPace RNS system for epilepsy, and the Guardian cardiac monitor. He is currently involved with Avertix Medical regarding the Peregrine catheter for blood pressure treatment and has co-founded TETmedical to commercialize a new blood test for stroke.